Last reviewed · How we verify
NCT06683885
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 1, PHASE2 trial testing Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone in Newly Diagnosed Diffuse Large B-cell Lymphoma in 80 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | Mingzhi Zhang |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 20 November 2024 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone — full drug profile →
Conditions studied
- Newly Diagnosed Diffuse Large B-cell Lymphoma — all drugs for Newly Diagnosed Diffuse Large B-cell Lymphoma →
Sponsor
Mingzhi Zhang — full company profile →
Who can join
65 and older, any sex, with Newly Diagnosed Diffuse Large B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment.
Caloian AD, Cristian M, Calin E, Pricop AR, et al · · 2025 · cited 7× · PMID 40299416 · DOI 10.3390/biomedicines13040853
Verify or expand the search:
- PubMed search for NCT06683885
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Mingzhi Zhang trials
Trials by the same sponsor.
- NCT06647329 — CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors · Phase 1 · not yet recruiting
- NCT06559553 — "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL · Phase 1, PHASE2 · recruiting
- NCT04831658 — A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervou · Phase 1, PHASE2 · unknown
- NCT04083066 — Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous Sys · Phase 4 · unknown
- NCT04040491 — PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06683885 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mingzhi Zhang
- Last refreshed: 12 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06683885.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing